SCHEMBL39569

SCHEMBL39569

C=C1CCC(C(=O)O)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 3/20 0.44
GABRD O14764 3/20 0.44
GABRA1 P14867 3/20 0.44
GABRB1 P18505 3/20 0.44
GABRG2 P18507 3/20 0.44
GABRB3 P28472 3/20 0.44
GABRA5 P31644 3/20 0.44
GABRA3 P34903 3/20 0.44
GABRA2 P47869 3/20 0.44
GABRB2 P47870 3/20 0.44
GABRA4 P48169 3/20 0.44
GABRE P78334 3/20 0.44
GABRA6 Q16445 3/20 0.44
GABRG1 Q8N1C3 3/20 0.44
GABRG3 Q99928 3/20 0.44
GABRQ Q9UN88 3/20 0.44
TSHR P16473 3/20 0.44
PMP22 Q01453 1/20 0.44
GABRR1 P24046 1/20 0.43
LMNA P02545 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4450777 0.90 PLG (0.44) GABRPGABRDGABRA1GABRB1GABRG2
Cyclopropane Carboxylic Acid SCHEMBL11837794 0.90 PLG (0.44) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL21880540 0.86 MEN1 (0.41) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL12423753 0.85
SCHEMBL5729035 0.85
SCHEMBL15684113 0.85
SCHEMBL1665954 0.83 GABRP (0.39) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL9464879 0.80 BTK (0.36) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL13280678 0.77 LMNA (0.37) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL14669060 0.77 SMN1; SMN2 (0.39) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119101069-A Spiro compounds and uses thereof 轩竹生物科技股份有限公司 2024-12-10 CN disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
CN-110177783-A Hormone receptor modulators for the treatment of metabolic conditions and disorders 阿德利克斯股份有限公司 2019-08-27 CN disclosed
CN-105111210-B Condensed imidazole derivatives as IDO inhibitor 新联基因公司 2018-10-09 CN disclosed
EP-3019196-B1 COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-06-06 EP disclosed
US-9976165-B2 Methods for increasing molecular diversity of polyketides and non-ribosomal proteins ISOMERASE THERAPEUTICS, LTD. (GB) 2018-05-22 US disclosed
US-9976165-B2 Methods for increasing molecular diversity of polyketides and non-ribosomal proteins ISOMERASE THERAPEUTICS, LTD. (GB) 2018-05-22 US disclosed
EP-2802326-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-04-18 EP disclosed
US-9770439-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-09-26 US disclosed
US-9770439-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-09-26 US disclosed
EP-0313297-B1 PROCESS FOR PRODUCTION OF AVERMECTIN AGLYCONES AND CULTURES THEREFOR PFIZER INC. (US) 1993-05-19 EP disclosed
EP-0316124-B1 ETHYLATED AVERMECTINS PFIZER INC. (US) 1993-04-07 EP disclosed
EP-0276131-B1 NON-NATURAL DEMETHYLAVERMECTINS AND PROCESS THEREFOR PFIZER INC. (US) 1993-04-07 EP disclosed
US-5089480-A ANTIPARASITIC AGENTS PFIZER INC. (US) 1992-02-18 US disclosed
US-5077278-A Parasiticides PFIZER INC. (US) 1991-12-31 US disclosed
EP-0316124-A2 Ethylated avermectins PFIZER INC. (US) 1989-05-17 EP disclosed
EP-0313297-A2 Process for production of avermectin aglycones and cultures therefor PFIZER INC. (US) 1989-04-26 EP disclosed
EP-0284176-A2 Process for production of avermectins and cultures therefor PFIZER INC. (US) 1988-09-28 EP disclosed
EP-0276103-A2 Process for production of B avermectins and cultures therefor PFIZER INC. (US) 1988-07-27 EP disclosed
EP-0276131-A2 Non-natural demethylavermectins and process therefor PFIZER INC. (US) 1988-07-27 EP disclosed